## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/18962

A. CLA	SSIFICATION OF SUBJECT MATTER	101/0304/18902			
PC(7)	: CO7H 21/04; A61K 48/00: CO7K 14/00 14/	/52			
US CL	. J3U/43.1.21 4' \1//// 520/250 251				
According to International Patent Classification (IPC) or to both national classification and IPC  B. FIELDS SEARCHED					
Minimum do U.S. : 5	ocumentation searched (classification system followe 36/23.1, 23.4; 514/44; 530/350, 351	d by classification symbols)			
Documentati	on searched other than minimum d				
	on searched other than minimum documentation to t	he extent that such documents are included	in the fields searched		
Plantania da	A-1				
Please See C	ata base consulted during the international search (ne continuation Sheet	ame of data base and, where practicable, sea	rch terms used)		
C. DOC	UMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where	appropriet - 64			
X	US 2002/0123099 A1 (WEINER et al.) 5 Septemb	er 2002 (5.0.2002)	Relevant to claim No.		
- Y	, and the sophering	2002 (J.F.2002), see entire document	38-40, 48, 49-53		
			1-4, 25, 26, 27, 37, 47		
Y	RUCKERT et al. II-15-IgG2b fusion protein accelerates and enhances a TH2 but not a Th1 immune response in vivo, while II-2-IgG2b fusion protein inhibits both. Eur. J. Immunol.  1-4, 7, 25, 26, 27, 29, December 1998, Vol. 28: 3312-3320  37, 47				
Y	WIERDA et al. CD40-ligand (CD145) gene therapy for chronic lymphocytic leukemia.  7, 25				
Y					
•	ANETHER et al. Interleukin-15 as a potential costimulatory cytokine in CD154 gene therapy of chronic lymphocytic leukemia. Blood. Vol 99, pages 722-723, see entire document 7, 25				
	propries sympholytic reakenita, Blood, Voi 99, pr	ages 722-723, see entire document			
		·			
Further documents are listed in the continuation of Box C.  See patent family annex.					
Sį	ocial categories of cited documents:	"T" later document muhlished of the inter-			
"A" document particular i	defining the general state of the art which is not considered to be of elevance	and not in conflict with the application by principle or theory underlying the inventi			
	lication or patent published on or after the international filing date	"X" document of particular relevance; the clair considered novel or cannot be considered when the document is below.	med invention cannot be		
L" document : establish ti	which may throw doubts on priority claim(s) or which is cited to	The discontinuit is taken alone			
specified)	ne publication date of another citation or other special reason (as	document of particular relevance; the clair	med invention cannot be		
	referring to an onal disclosure, use, exhibition or other means	considered to involve an inventive step w with one or more other such documents, s to a person skilled in the art	them the dearest to the terms of the terms o		
"P" document published prior to the international filing date but later than the priority date claimed		"&" document member of the same patent for	nily		
Date of the ac	Date of the actual completion of the				
	5 (04.03.2005)	Date of mailing of the international search	1 report		
Vame and mai	Uing address of the ISA/US	OT APP Shirt	<i>i</i>		
Mail	Stop PCT, Attn: ISA/I is	Authorized officer	21 6-1-3		
Com	missioner for Patents Box 1450	Ram Shukla	UUT		
Alexandria, Virginia 22313-1450					
acsimile No.	(703) 305-3230	1			
rm PCT/ISA/	210 (second sheet) (January 2004)	<u> </u>			

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US04/18962

Box No. II	Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)		
This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:			
1.	Claims Nos.:  because they relate to subject matter not required to be searched by this Authority, namely:		
1	Claims Nos.: 35 and 36 because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically: Claims 35 and 36 depend on claims 58 or 60 and claims 59,62 or 64-67, respectively. Claims 58-60, 62 and 64-67 were not filed with this application.		
	Claims Nos.: 5,6,8,12-24,28,34-36 and 41-46 because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).		
Box No. III	Observations where unity of invention is lacking (Continuation of item 3 of first sheet)		
This Internation	nal Searching Authority found multiple inventions in this international application, as follows:		
2.	As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.  As only some of the required additional search fees were timely paid by the applicant, this international search report overs only those claims for which fees were paid, specifically claims Nos.:		
4. N re Remark on Pro	To required additional search fees were timely paid by the applicant. Consequently, this international search report is estricted to the invention first mentioned in the claims; it is covered by claims Nos.:  The additional search fees were accompanied by the applicant's protest.  No protest accompanied the payment of additional search fees.		

INTERNATIONAL SEARCH REPORT	International application No.	
THE STATE OF THE S	PCT/US04/18962	
	•	
Continuation of D. FIELDS ST. L. D.	•	
Continuation of B. FIELDS SEARCHED Item 3: STN: Medline		
Search Terms II-15 fusion protein, IgE signal peptide, CD40L, CD154, leader sequences	1190.00	
. , o specification, oblish, teader sequ	uerce	
	,	
	•	
	•	

Form PCT/ISA/210 (extra sheet) (January 2004)